Press release
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. “I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval and launch of losmapimod for the treatment of FSHD,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “Isabel has a proven track record of highly successful rare disease drug launches including the launch of ELAHERE® and TAKHZYRO®. With her leadership and experience, we are well positioned to transform Fulcrum Therapeutics into a commercial-stage biotechnology company.” Mr. Sapir continued, “We are equally excited to have Heather join our leadership team. Heather brings deep knowledge of the neuromuscular landscape and experience in designing and implementing innovative regulatory strategies. During her tenure at Biogen, Heather led the global filing for SPINRAZA® for the treatment of spinal muscular atrophy, which was approved by the FDA under priority review designation in 90 days. Heather’s expertise will be invaluable as we continue to prepare for the NDA filing and potential approval of losmapimod.” Isabel Kalofonos, Chief Commercial Officer Ms. Kalofonos joins Fulcrum from ImmunoGen where she served as Senior Vice President and Chief Commercial Officer. While at ImmunoGen, Ms. Kalofonos led commercial efforts globally for the launch of ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Prior to ImmunoGen, she served as Senior Vice President and Global Head of the Prescription Business Unit at Galderma. During her tenure, she led the launch preparation for NEMLUVIO® (nemolizumab), a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, which included marketing, glob...